A Novel Selective BCL2 Inhibitor with Limited Immune Suppression and Improved Safety Compared to Venetoclax

被引：1
|
作者：
Sharpe, Chia [1 ]
Elgamal, Sara [1 ]
Fobare, Sydney [2 ]
Furby, Casie [1 ]
Long, Marissa [1 ]
Bryant, Kinsey [1 ]
Cheney, Carolyn [1 ]
Lerma, James R. [1 ]
Johnstone, Megan E. [1 ]
Orry, Andrew [3 ]
Lam, Polo Chun-Hung [3 ]
Abagyan, Ruben [3 ]
Kysil, Volodymyr [4 ]
Gukasyan, Hovhannes [4 ]
Mitkin, Oleg [4 ]
Karapetian, Ruben [4 ]
Ryakhovskiy, Alexey [4 ]
Bulanova, Elena [4 ]
Parchinsky, Vladislav [4 ]
Ivachtchenko, Alexandre [4 ]
Dokukina, Kate [5 ]
Pushechnikov, Alexei [4 ]
Savchuk, Nikolay [5 ]
Dukes, Iain [5 ]
Burd, Amy [5 ]
Hertlein, Erin K. [1 ]
Byrd, John C. [1 ]
机构：
[1] Univ Cincinnati, Dept Internal Med, Cincinnati, OH USA
[2] Ohio State Univ, Med Scientist Training Program, Columbus, OH USA
[3] MolSoft LLC, San Diego, CA USA
[4] ChemDiv Inc, San Diego, CA USA
[5] Eilean Therapeut, Philadelphia, PA USA
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-189266
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Rationale for Combining the BCL2 Inhibitor Venetoclax with the PI3K Inhibitor Bimiralisib in the Treatment of IDH2-and FLT3-Mutated Acute Myeloid Leukemia
    Seipel, Katja
    Bruegger, Yvo
    Mandhair, Harpreet
    Bacher, Ulrike
    Pabst, Thomas
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (20)
  • [42] Safety, Efficacy, and PK of the BCL2 Inhibitor Venetoclax in Combination with Chemotherapy in Pediatric and Young Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia: Phase 1 Study
    Karol, Seth E.
    Cooper, Todd M.
    Bittencourt, Henrique
    Gore, Lia
    O'Brien, Maureen M.
    Fraser, Christopher
    Gambart, Marion
    Cario, Gunnar
    Zwaan, Christian Michel
    Bourquin, Jean-Pierre
    Loh, Mignon L.
    Caron, Hubert
    Prine, Betty
    Salem, Ahmed Hamed
    Unnebrink, Kristina
    Tong, Bo
    Palenski, Tammy
    Place, Andrew E.
    BLOOD, 2019, 134
  • [43] The selective Bcl-2 inhibitor venetoclax, a BH3 mimetic, does not dysregulate intracellular Ca2+ signaling
    Vervloessem, Tamara
    Ivanova, Hristina
    Luyten, Tomas
    Parys, Jan B.
    Bultynck, Geert
    BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH, 2017, 1864 (06): : 968 - 976
  • [44] Preliminary Safety and Efficacy Of BGB-11417, a Potent and Selective B-Cell Lymphoma 2 (BCL2) Inhibitor, in Patients (Pts) with Acute Myeloid Leukemia (AML)
    Shortt, Jake
    Platzbecker, Uwe
    Tan, Shuh Ying
    Cannell, Paul
    Ng, Teng Fong
    Fong, Chun Yew
    Ramanathan, Sundra
    Rajagopal, Rajeev
    Leitch, Sophie
    Gasiorowski, Robin
    Grove, Carolyn
    Lenton, Douglas
    Tan, Peter
    Dinardo, Courtney
    Ling, Ming Tat
    Cheng, Si
    Liu, Yuan
    Co, Melannie
    Chan, Wai Y.
    Simpson, David
    Wei, Andrew H.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 144 - 144
  • [45] Cyclin dependent kinase 4/6 inhibitor palbociclib synergizes with BCL2 inhibitor venetoclax in experimental models of mantle cell lymphoma without RB1 deletion
    Malarikova, Diana
    Jorda, Radek
    Kupcova, Kristyna
    Senavova, Jana
    Dolnikova, Alexandra
    Pokorna, Eva
    Kazantsev, Dmitry
    Nozickova, Kristina
    Sovilj, Dana
    Bellanger, Celine
    Chiron, David
    Andera, Ladislav
    Krystof, Vladimir
    Strnad, Miroslav
    Helman, Karel
    Klanova, Magdalena
    Trneny, Marek
    Havranek, Ondrej
    Klener, Pavel
    EXPERIMENTAL HEMATOLOGY & ONCOLOGY, 2024, 13 (01)
  • [46] Elevated Expression of the S100A8/S100A9 Complex in AML Correlates with Reduced Sensitivity to the BCL2 Inhibitor Venetoclax
    Karjalainen, Riikka
    Liu, Minxia
    Kumar, Ashwini
    Parsons, Alun
    Kontro, Mika
    Porkka, Kimmo
    Heckman, Caroline A.
    BLOOD, 2017, 130
  • [47] Cyclin dependent kinase 4/6 inhibitor palbociclib synergizes with BCL2 inhibitor venetoclax in experimental models of mantle cell lymphoma without RB1 deletion
    Diana Malarikova
    Radek Jorda
    Kristyna Kupcova
    Jana Senavova
    Alexandra Dolnikova
    Eva Pokorna
    Dmitry Kazantsev
    Kristina Nozickova
    Dana Sovilj
    Celine Bellanger
    David Chiron
    Ladislav Andera
    Vladimir Krystof
    Miroslav Strnad
    Karel Helman
    Magdalena Klanova
    Marek Trneny
    Ondrej Havranek
    Pavel Klener
    Experimental Hematology & Oncology, 13
  • [48] LP-118, a Novel BCL2 Inhibitor, Shows Potent in Vitro Anti-Myeloma Activity
    Fonseca, Rodrigo
    Zhu, Yuan Xiao
    Bergsagel, P. Leif
    Chesi, Marta
    Pandey, Akhilesh
    Mangalaparthi, Kiran
    Chen, Yi
    Tan, Felai
    Anthony, Stephen P.
    Chen, Yu
    Shen, Yue
    Dai, Bing
    Braggio, Esteban
    Fonseca, Rafael
    BLOOD, 2022, 140 : 7129 - 7130
  • [49] The BCL-2-Selective Inhibitor Venetoclax Spares Activated T-Cells during Anti-Tumor Immunity
    Mathew, Rebecca
    Haribhai, Dipica
    Kohlhapp, Fred
    Duggan, Ryan
    Ellis, Paul
    Riehm, Jacob J.
    Robinson, Valerie A.
    Shi, Yan Y.
    Bhathena, Anahita
    Leverson, Joel D.
    Pappano, William N.
    Donawho, Cherrie K.
    Uziel, Tamar
    BLOOD, 2018, 132
  • [50] Efficacy and Safety of Bcl-2 Inhibitor Venetoclax in Hematological Malignancy: A Systematic Review and Meta-Analysis of Clinical Trials
    Li, Qingfang
    Cheng, Li
    Shen, Kai
    Jin, Hongyu
    Li, Hui
    Cheng, Yuan
    Ma, Xuelei
    FRONTIERS IN PHARMACOLOGY, 2019, 10
12345